Y-mAbs (YMAB) Q2 Revenue Falls 14%

Y-mAbs Therapeutics (NASDAQ:YMAB), a biopharmaceutical company focused on developing and commercializing antibody-based cancer therapies, reported its second quarter 2025 results on August 8, 2025. The company beat expectations on both revenue and earnings per share, posting GAAP revenue of $19.5 million against a GAAP consensus of $18.4 million, and GAAP EPS of ($0.07) compared to an analyst estimate of ($0.26). However, revenue dropped 14% from the prior year, mainly due to lower product sales. The quarter showed better-than-expected headline financials, but underlying results highlighted ongoing sales pressures and continued reliance on the company’s core product, DANYELZA. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Y-mAbs Therapeutics develops and commercializes immunotherapies for cancer. Its main focus is on antibody-based products, including its core commercial product, DANYELZA, which is used to treat GD2-positive tumors in pediatric neuroblastoma patients. DANYELZA is currently the company’s only approved drug and accounts for nearly all product revenue.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool